These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36774435)

  • 1. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study.
    Michiels N; Doppenberg D; Groen JV; van Veldhuisen E; Bonsing BA; Busch OR; Crobach ASLP; van Delden OM; van Dieren S; Farina A; de Hingh IHJT; Hurks R; Nederend J; Shahbazi Feshtali S; Tank Y; Vahrmeijer AL; Wasser M; Besselink MG; Mieog JSD;
    Ann Surg Oncol; 2023 Jun; 30(6):3455-3463. PubMed ID: 36774435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction Therapy in Localized Pancreatic Cancer.
    Shaib WL; Sayegh L; Zhang C; Belalcazar A; Ip A; Alese OB; Akce M; Wu C; Qu Y; Maithel SK; Kooby D; Cardona K; Sarmeinto JM; El-Rayes BF
    Pancreas; 2019 Aug; 48(7):913-919. PubMed ID: 31268982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
    Okada KI; Kawai M; Hirono S; Kojima F; Tanioka K; Terada M; Miyazawa M; Kitahata Y; Iwahashi Y; Ueno M; Hayami S; Murata SI; Shimokawa T; Yamaue H
    Langenbecks Arch Surg; 2020 Feb; 405(1):23-33. PubMed ID: 31993737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
    van Veldhuisen E; Klompmaker S; Janssen QP; Hilal MA; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Conlon KC; Frigerio IM; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Keck T; Kleeff J; Klaiber U; Labori KJ; Lesurtel M; Malleo G; Marino MV; Molenaar IQ; Mortensen MB; Nikov A; Pagnanelli M; Pandé R; Pfeiffer P; Pietrasz D; Rangelova E; Roberts KJ; Cunha AS; Salvia R; Strobel O; Tarvainen T; Wilmink JW; Koerkamp BG; Besselink MG;
    Ann Surg Oncol; 2023 Mar; 30(3):1463-1473. PubMed ID: 36539580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer.
    Sibinga Mulder BG; Feshtali S; Fariña Sarasqueta A; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Ultrasound Med Biol; 2019 Aug; 45(8):2019-2026. PubMed ID: 31130412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
    Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
    BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
    Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
    Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113).
    Guggenberger KV; Bley TA; Held S; Keller R; Flemming S; Wiegering A; Germer CT; Kimmel B; Kunzmann V; Hartlapp I; Anger F
    Eur J Radiol; 2023 Jun; 163():110834. PubMed ID: 37080059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.